TECHNOLOGY
Field of research
We pour all our energy into the development and demonstration of innovative, super-gap enabling technologies related to the full-cycle purification process of protein-based biopharmaceuticals, maximizing the advantages offered by the next-generation purification platform (MIDAS™).
R&D
-
Development of platform technology
-
Development of manufacturing and purification processes
-
Enabling technology and method of analysis
- · MIDAS™ purification platform technology-based demonstration of technologies on a large-scale.
- · Intelligent Protein A/L for antibody purification.
- · Smart eraser system for removing purification tags.
Possessing our biopharmaceutical-related R&D capabilities.
Purification process-related problems in biopharmaceutical manufacturing.
Around 45-92 percent of biopharmaceutical manufacturing costs are incurred in the downstream process.
(Saraswat et al., 2013; Straathof, 2011; Lowe, 2001)
The following factors impose restriction on the scale-up of biopharmaceutical manufacturing.
(Saraswat et al., 2013; Straathof, 2011; Lowe, 2001)
The following factors impose restriction on the scale-up of biopharmaceutical manufacturing.
-
- High purification costs
- Need for expensive affinity resin/columns and advanced operating equipment (facilitates), large-volume buffers required, etc.
-
- Time-consuming
- 1~4days
-
- Complexity of the purification process
- affinity-/ion exchange-/size exclusion-/polishing-chromatography, filtration such as UF/DF, etc.
-
- Contamination with non-specific proteins.
-
- Use of large volumes of buffer, resulting in a high output of byproducts.
-
- Limitations in the cross-use of resins and columns in the manufacturing line.
It is vital to develop new and original purification technology in order to overcome the bottleneck situation and to achieve global competitiveness by securing the technological independence of biopharmaceutical industry in South Korea.
- South Korea ranks No.2 in the field of biopharmaceutical manufacturing in the world.
-
National localization rate for
biopharmaceutical manufacturing
raw materials in South Korea ≤5%.
More than $1.47 billion worth of
national wealth flows out of the country
each year due to the importation of
purification resins, media, filters, etc. - Therefore, we must develop original and innovative super-gap technologies for the full-cycle purification process in order to resolve this problem.